Liposomal palmitoyl-L-asparaginase: characterization and biological activity

João C S Jorge, Roman Perez-Soler, José G. Morais, Maria Eugénia M Cruz

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A new derivative of L-asparaginase, palmitoyl-L-asparaginase (palmitoyl-L-ASNase), has been incorporated in liposomes. For this purpose we modified the dehydration-rehydration method and optimized the liposomal composition. The pharmacokinetics, toxicity, and in vivo antitumor activity against P1534 lymphoma of different liposomal palmitoyl-L-ASNase formulations were studied. Liposomal encapsulation of palmitoyl-L-ASNase as compared with free palmitoyl-L-ASNase resulted in a prolongation of the blood half-life (from 2.88 h to longer than 23.7 h), abrogation of acute toxicity, and preservation of in vivo antitumor activity.

Original languageEnglish (US)
Pages (from-to)230-234
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume34
Issue number3
DOIs
StatePublished - May 1994
Externally publishedYes

Fingerprint

Bioactivity
Toxicity
Pharmacokinetics
Fluid Therapy
Dehydration
Encapsulation
Liposomes
Half-Life
Lymphoma
Blood
Derivatives
palmitoyl-L-asparaginase
Chemical analysis

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Liposomal palmitoyl-L-asparaginase : characterization and biological activity. / Jorge, João C S; Perez-Soler, Roman; Morais, José G.; Cruz, Maria Eugénia M.

In: Cancer Chemotherapy and Pharmacology, Vol. 34, No. 3, 05.1994, p. 230-234.

Research output: Contribution to journalArticle

Jorge, João C S ; Perez-Soler, Roman ; Morais, José G. ; Cruz, Maria Eugénia M. / Liposomal palmitoyl-L-asparaginase : characterization and biological activity. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 34, No. 3. pp. 230-234.
@article{0a6894bfd0e74ac59aa24a7af337f210,
title = "Liposomal palmitoyl-L-asparaginase: characterization and biological activity",
abstract = "A new derivative of L-asparaginase, palmitoyl-L-asparaginase (palmitoyl-L-ASNase), has been incorporated in liposomes. For this purpose we modified the dehydration-rehydration method and optimized the liposomal composition. The pharmacokinetics, toxicity, and in vivo antitumor activity against P1534 lymphoma of different liposomal palmitoyl-L-ASNase formulations were studied. Liposomal encapsulation of palmitoyl-L-ASNase as compared with free palmitoyl-L-ASNase resulted in a prolongation of the blood half-life (from 2.88 h to longer than 23.7 h), abrogation of acute toxicity, and preservation of in vivo antitumor activity.",
author = "Jorge, {Jo{\~a}o C S} and Roman Perez-Soler and Morais, {Jos{\'e} G.} and Cruz, {Maria Eug{\'e}nia M}",
year = "1994",
month = "5",
doi = "10.1007/BF00685082",
language = "English (US)",
volume = "34",
pages = "230--234",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Liposomal palmitoyl-L-asparaginase

T2 - characterization and biological activity

AU - Jorge, João C S

AU - Perez-Soler, Roman

AU - Morais, José G.

AU - Cruz, Maria Eugénia M

PY - 1994/5

Y1 - 1994/5

N2 - A new derivative of L-asparaginase, palmitoyl-L-asparaginase (palmitoyl-L-ASNase), has been incorporated in liposomes. For this purpose we modified the dehydration-rehydration method and optimized the liposomal composition. The pharmacokinetics, toxicity, and in vivo antitumor activity against P1534 lymphoma of different liposomal palmitoyl-L-ASNase formulations were studied. Liposomal encapsulation of palmitoyl-L-ASNase as compared with free palmitoyl-L-ASNase resulted in a prolongation of the blood half-life (from 2.88 h to longer than 23.7 h), abrogation of acute toxicity, and preservation of in vivo antitumor activity.

AB - A new derivative of L-asparaginase, palmitoyl-L-asparaginase (palmitoyl-L-ASNase), has been incorporated in liposomes. For this purpose we modified the dehydration-rehydration method and optimized the liposomal composition. The pharmacokinetics, toxicity, and in vivo antitumor activity against P1534 lymphoma of different liposomal palmitoyl-L-ASNase formulations were studied. Liposomal encapsulation of palmitoyl-L-ASNase as compared with free palmitoyl-L-ASNase resulted in a prolongation of the blood half-life (from 2.88 h to longer than 23.7 h), abrogation of acute toxicity, and preservation of in vivo antitumor activity.

UR - http://www.scopus.com/inward/record.url?scp=0028283530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283530&partnerID=8YFLogxK

U2 - 10.1007/BF00685082

DO - 10.1007/BF00685082

M3 - Article

C2 - 8004756

AN - SCOPUS:0028283530

VL - 34

SP - 230

EP - 234

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -